X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (38) 38
male (35) 35
index medicus (34) 34
prostate cancer (26) 26
oncology (20) 20
aged (18) 18
article (18) 18
middle aged (18) 18
chemotherapy (16) 16
prostatic neoplasms - pathology (15) 15
mice (14) 14
adult (13) 13
animals (13) 13
prostatic neoplasms - drug therapy (13) 13
cancer (12) 12
metastasis (12) 12
antineoplastic agents - therapeutic use (11) 11
expression (11) 11
treatment outcome (11) 11
aged, 80 and over (10) 10
androgen receptor (10) 10
androgens (9) 9
castration (9) 9
increased survival (9) 9
bone neoplasms - secondary (8) 8
docetaxel (8) 8
immunohistochemistry (8) 8
prednisone (8) 8
prostatic neoplasms - metabolism (8) 8
research (8) 8
abiraterone acetate (7) 7
carcinoma (7) 7
cell biology (7) 7
cell line, tumor (7) 7
disease progression (7) 7
growth (7) 7
prostatic neoplasms - genetics (7) 7
prostatic neoplasms, castration-resistant - pathology (7) 7
receptors, androgen - metabolism (7) 7
survival (7) 7
tumors (7) 7
urology & nephrology (7) 7
abridged index medicus (6) 6
cells (6) 6
disease models, animal (6) 6
mice, scid (6) 6
receptors, androgen - genetics (6) 6
abiraterone (5) 5
androgen antagonists - therapeutic use (5) 5
antineoplastic agents - pharmacology (5) 5
cancer therapies (5) 5
disease-free survival (5) 5
double-blind method (5) 5
enzalutamide (5) 5
gene-expression (5) 5
hematology, oncology and palliative medicine (5) 5
inhibition (5) 5
mitoxantrone (5) 5
progression (5) 5
prostate (5) 5
prostatic neoplasms, castration-resistant - drug therapy (5) 5
transplantation, heterologous (5) 5
urology (5) 5
antineoplastic agents, hormonal - therapeutic use (4) 4
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
apoptosis (4) 4
biochemistry & molecular biology (4) 4
care and treatment (4) 4
clinical trials (4) 4
development and progression (4) 4
drug resistance, neoplasm (4) 4
female (4) 4
medicine, research & experimental (4) 4
men (4) 4
metastases (4) 4
neoplasm transplantation (4) 4
oncology, experimental (4) 4
pain (4) 4
pathology (4) 4
phenylthiohydantoin - analogs & derivatives (4) 4
phenylthiohydantoin - therapeutic use (4) 4
phosphorylation (4) 4
prognosis (4) 4
prostate-specific antigen - blood (4) 4
prostatic neoplasms - surgery (4) 4
prostatic neoplasms, castration-resistant - metabolism (4) 4
signal transduction - drug effects (4) 4
steroid 17-alpha-hydroxylase - antagonists & inhibitors (4) 4
studies (4) 4
survival analysis (4) 4
tissue array analysis (4) 4
xenograft model antitumor assays (4) 4
xenografts (4) 4
adenocarcinoma - drug therapy (3) 3
adenocarcinoma - metabolism (3) 3
age factors (3) 3
androgen receptor antagonists - therapeutic use (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
biomarkers, tumor - analysis (3) 3
biomarkers, tumor - metabolism (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2010, Volume 375, Issue 9724, pp. 1437 - 1446
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 9, pp. e404 - e414
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 12, pp. 1210 - 1217
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 13, pp. 1307 - 1316
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 3, pp. 338 - 348
Summary Background Orteronel is an investigational, partially selective inhibitor of CYP 17,20-lyase in the androgen signalling pathway, a validated... 
Hematology, Oncology and Palliative Medicine | MITOXANTRONE | ONCOLOGY | MEN | END-POINTS | ABIRATERONE ACETATE | INCREASED SURVIVAL | DOCETAXEL | ENZALUTAMIDE | Steroid 17-alpha-Hydroxylase - antagonists & inhibitors | Prostatic Neoplasms, Castration-Resistant - enzymology | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Male | North America | Prostatic Neoplasms, Castration-Resistant - pathology | Time Factors | Prednisone - administration & dosage | Double-Blind Method | Europe | Risk Factors | Adenocarcinoma - enzymology | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Prostatic Neoplasms, Castration-Resistant - drug therapy | Adenocarcinoma - drug therapy | Cytochrome P-450 Enzyme Inhibitors - administration & dosage | Adenocarcinoma - secondary | Disease Progression | New Zealand | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Asia | Naphthalenes - administration & dosage | Intention to Treat Analysis | Aged | Prostatic Neoplasms, Castration-Resistant - mortality | Steroid 17-alpha-Hydroxylase - metabolism | Australia | Adenocarcinoma - mortality | Medical colleges | Care and treatment | Chemotherapy | Corticosteroids | Cytochrome P-450 | Clinical trials | Prednisone | Metastasis | Prostate cancer | Cancer | Steroids
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2011, Volume 364, Issue 21, pp. 1995 - 2005
Journal Article
Nature Medicine, ISSN 1078-8956, 05/2017, Volume 23, Issue 5, pp. 551 - 555
Journal Article